Clinical trials: Respiratory Tract Infection
Covid19
A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19
This is phase II study to evaluate the safety and efficacy of inhaled Ampion in adults with respiratory distress due to COVID-19
- Trial name
- NCT04868890
- Testing
- Ampion
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Ampio Pharmaceuticals. Inc.
Influenza, Human
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
- Trial name
- NCT01527110
- Testing
- Intravenous (IV) zanamivir
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
SARS-CoV2, COVID-19
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended…
- Trial name
- NCT06672055
- Testing
- VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
- Where
- 145 sites in United States
- Volunteers
- 5,485 people
- Sponsor
- Vaxart
Influenza
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
- Trial name
- NCT00620815
- Testing
- Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- Where
- 2 sites in Germany
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza Disease
Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of a Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, when Administered to Non-Elderly Adults and…
- Trial name
- NCT00316615
- Testing
- influenza vaccine
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Novartis
Allergic Rhinitis, Upper Respiratory Infection
Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children
The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years.
- Trial name
- NCT00796315
- Testing
- Doxylamine Succinate USP
- Where
- 6 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Influenza
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
The study will evaluate the safety and immunogenicity of the 2015-2016 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory Committee on Immunization Practices…
- Trial name
- NCT02539108
- Testing
- Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
The purpose of this study is to assess the reactogenicity, safety and immunogenicity of different formulations of GlaxoSmithKline (GSK) Biologicals' investigational supra-seasonal universal influenza vaccines (SUIVs)…
- Trial name
- NCT03275389
- Testing
- D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03
- Where
- 6 sites in United States, Belgium
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly
The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).
- Trial name
- NCT00772889
- Testing
- Influenza vaccine GSK2186877A, GSK Biologicals' Fluarix™
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Tract Disease, Influenza
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
The purpose of the study on the Prevention of Influenza and Other Wintertime Respiratory Viruses among Healthcare Professionals in Israel Effectiveness of Influenza Vaccine in Preventing Influenza Virus Infection, Missed Work…
- Trial name
- HCP (NCT03331991)
- Testing
- influenza vaccine
- Where
- 2 sites in Israel
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Abt Associates
Pharyngitis
Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis
The purpose of this trial is to investigate efficacy and tolerability of lozenges containing 20mg am broxol hydrochloride relative to placebo in relieving pain of sore throat in adolescent patients suf fering from acute viral…
- Trial name
- NCT00144274
- Testing
- Ambroxol Lozenge
- Where
- 12 sites in South Africa
- Volunteers
- 220 people
- Sponsor
- Boehringer Ingelheim
Pneumonia, Ventilator Associated Pneumonia
Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa
The objectives of this open study are to assess the safety, tolerability, pharmacokinetics and clinical outcome of patients who have HAP caused by Pseudomonas aeruginosa serotype O11 after three separate administrations of…
- Trial name
- NCT00851435
- Testing
- KBPA-101
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- Kenta Biotech Ltd
RSV Infection, Drug Drug Interaction
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.
- Trial name
- NCT06917508
- Testing
- EDP-323, Midazolam, Caffeine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Cystic Fibrosis, Burkholderia Infection
A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection
The purpose of the study is to assess the efficacy of Alginate oligosaccharide (OligoG) dry powder for inhalation in cystic fibrosis (CF) patients with a Burkholderia spp. infection.
- Trial name
- SMR-2591 (NCT02453789)
- Testing
- Alginate oligosaccharide
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- AlgiPharma AS
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mantle Cell Lymphoma, COVID-19
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
This Phase 1 study is being conducted to support the clinical development of acalabrutinib in hospitalized patients who are unable to swallow acalabrutinib tablet or capsule due to respiratory failure, eg, they may require…
- Trial name
- NCT04564040
- Testing
- Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19
DAS181 for STOP COVID-19
It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of…
- Trial name
- NCT04354389
- Testing
- DAS181
- Where
- 2 sites in Italy
- Sponsor
- Ansun Biopharma, Inc.
Pertussis (Whooping Cough), Diphtheria
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
the immunogenicity and safety of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
- Conditions
- Pertussis (Whooping Cough), Diphtheria, Tetanus
- Trial name
- NCT07894055
- Testing
- Tdap vaccine
- Where
- China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Cytokine Release Syndrome in COVID-19-induced Pneumonia
Canakinumab MAP in COVID-19 Pneumonia With CRS
This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia
- Trial name
- NCT04476706
- Testing
- canakinumab
- Sponsor
- Novartis Pharmaceuticals